Branson

Branson Pharma AG is a Swiss biotechnology company focused on developing a portfolio of treatments for challenging conditions in gynaecology, central nervous system (CNS) disorders, and cardiovascular health. The company's lead development program is a proprietary biomolecule designed to treat chronic gynaecologic infections and inflammatory conditions, including endometriosis, endometritis, and adenomyosis. This therapeutic candidate utilizes a unique mechanism of action that selectively targets infected cells and dissolves necrotic tissue by breaking it down into basic amino acids. Early testing of the molecule has demonstrated high efficacy and a rapid treatment rate, positioning it as a potential curative option for patients with limited alternatives. Founded in 2022 and headquartered in Baar, Switzerland, Branson Pharma is currently advancing its pipeline through pre-clinical stages while seeking strategic partnerships for manufacturing and further clinical development.